MARKET

KPTI

KPTI

Karyopharm Therapeutics Inc
NASDAQ
7.94
-0.81
-9.26%
Opening 14:37 03/12 EDT
OPEN
8.70
PREV CLOSE
8.75
HIGH
8.78
LOW
7.65
VOLUME
604.74K
TURNOVER
--
52 WEEK HIGH
10.99
52 WEEK LOW
3.510
MARKET CAP
145.65M
P/E (TTM)
-0.4429
1D
5D
1M
3M
1Y
5Y
1D
This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga · 2d ago
Karyopharm initiated with a Buy at Rodman & Renshaw
TipRanks · 3d ago
Weekly Report: what happened at KPTI last week (0302-0306)?
Weekly Report · 3d ago
Analysts’ Top Healthcare Picks: Citius Oncology (CTOR), Karyopharm Therapeutics (KPTI)
TipRanks · 5d ago
Analysts Are Bullish on These Healthcare Stocks: Evolus (EOLS), Aldeyra Therapeutics (ALDX)
TipRanks · 03/04 11:30
Karyopharm Amends Credit Agreement to Extend Liquidity Runway
TipRanks · 03/03 11:36
KARYOPHARM THERAPEUTICS INC - AMENDMENT ALLOWS CO DEFERRAL OF PAYMENTS UNTIL SEPTEMBER 2026 - SEC FILING
Reuters · 03/03 11:02
KARYOPHARM THERAPEUTICS: AMENDMENT TO ELIMINATE REQUIREMENT THAT 50% OF FINANCING PROCEEDS BE APPLIED TOWARD INCREASING MINIMUM LIQUIDITY COVENANT
Reuters · 03/03 11:02
More
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.

Webull offers Karyopharm Therapeutics Inc stock information, including NASDAQ: KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.